A recent study of Aurora A kinase inhibitor MLN8054, MEK inhibitor trametinib, and BRAF inhibitor dabrafenib evaluated various combinations of these drugs in BRAF mutant melanoma cell lines (Caputo et al., 2014). This evidence concerns the gene BRAF and melanoma.